Suppr超能文献

高静压复性重组人血管内皮生长因子(VEGF)包涵体:复性优化及可行性评估。

High-pressure refolding of human vascular endothelial growth factor (VEGF) recombinantly expressed in bacterial inclusion bodies: refolding optimization, and feasibility assessment.

机构信息

Genentech, Pharma Technical Development, 1 DNA Way, South San Francisco, CA 94080, USA.

出版信息

Biotechnol Prog. 2011 Sep-Oct;27(5):1273-81. doi: 10.1002/btpr.642. Epub 2011 May 23.

Abstract

High-pressure has been established as an effective technique for refolding proteins at high concentrations. In this study, high hydrostatic pressure (1-3 kbar) was utilized to refold a homodimeric protein from inclusion bodies and the process was evaluated for large-scale manufacturing feasibility. This research focused on increasing protein concentration while maximizing yield and product quality. Refolding yields of 29-42% were achieved in the absence of urea at 2 kbar and at a protein concentration of 6 g/L. Optimization of the refolding buffer composition via multivariate design of experiments and other process parameters such as refolding pressure, gas sparging, and time under pressure are discussed. Although high-pressure refolding can be considered a viable technology for manufacturing if the gains are clearly identified, in this particular case, the benefits that the high-pressure technology offers do not compensate for the drawbacks of implementing new equipment in an existing facility, and unknown impact of scale-up for this molecule.

摘要

高压已被确立为在高浓度下使蛋白质重折叠的有效技术。在这项研究中,利用高静水压力(1-3kbar)从包涵体中重折叠同源二聚体蛋白,并评估了大规模生产的可行性。本研究的重点是在最大程度提高产量和产品质量的同时增加蛋白质浓度。在 2kbar 和 6g/L 的蛋白质浓度下,在没有尿素的情况下,重折叠产率达到 29-42%。通过多元设计实验优化了重折叠缓冲液的组成以及其他工艺参数,如重折叠压力、气体喷射和压力下的时间。虽然如果明确了收益,高压重折叠可以被认为是一种可行的制造技术,但在这种特殊情况下,高压技术提供的好处并不能弥补在现有设施中实施新设备的缺点,以及对这种分子放大的未知影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验